EXCEED THE SPACE PROVIDED. Tuberculosis is an reemerging disease, which after years of decline in the United States underwent an increase in incidence from 1985-1992. Lack of public health infrastructure, funding, and a general complacency that tuberculosis was a disease of the past contributed to this resurgence in the United States and the continuing increasing incidence worldwide. Among the many problems facing tuberculosis controllers is a lack of well- trained individuals.There is a significant need for clinicians who understand in many variations of tuberculosis infection and disease, and for biologists trained in handling this unique pathogen under appropriate conditions of biological safety. Johns Hopkins University has had a long-standing interest in tuberculosis research and control, beginning with the personal interest of professor William Osier who began studying this disease in Baltimore in 1898. Currently a cadre of about twenty faculty members have significant research interest in tuberculosis. These faculty members are spread throughout the University in both the faculty of the School of Medicine and the faculty of the School of Public Health. This proposal request support for two clinical fellows and two post- doctoral research fellows for training in tuberculosis. The resources of our university permit intensive clinical experience with U.S. patients treated for tuberculosis as well as clinical and research in human tuberculosis overseas in sites in Haiti, Brazil, Peru, and South Africa. In addition there is a significant research endeavor in the molecular pathogenesis, the pathology, the mechanisms of drug resistance, and the immunology of tuberculosis. This proposal will provide multidisciplinary training in both clinical aspects and basic science investigation in tuberculosis. Well-trained young investigators are essential for future tuberculosis control efforts =ERFORMANCE SITE{S) (organization, city, state) Johns Hopkins University School of Medicine Baltimore City Health Department -Tuberculosis Clinic KEY PERSONNEL ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
5T32AI007608-05
Application #
6929277
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Mcsweegan, Edward
Project Start
2001-09-01
Project End
2006-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
5
Fiscal Year
2005
Total Cost
$55,803
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Klinkenberg, Lee G; Sutherland, Lesley A; Bishai, William R et al. (2008) Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 198:275-83
Page, Kathleen R; Manabe, Yukari C; Adelakun, Akintoye et al. (2008) Timing of therapy for latent tuberculosis infection among immigrants presenting to a U.S. public health clinic: a retrospective study. BMC Public Health 8:158
Wade, Mary Margaret; Zhang, Ying (2006) Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 58:936-41
Page, Kathleen R; Sifakis, Frangiscos; Montes de Oca, Ruben et al. (2006) Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 166:1863-70
Karakousis, Petros C; Yoshimatsu, Tetsuyuki; Lamichhane, Gyanu et al. (2004) Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 200:647-57
Wade, Mary Margaret; Zhang, Ying (2004) Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 9:975-94
Wade, Mary Margaret; Zhang, Ying (2004) Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 53:769-73
Karakousis, Petros C; Moore, Richard D; Chaisson, Richard E (2004) Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 4:557-65
Zhang, Ying; Wade, Mary Margaret; Scorpio, Angelo et al. (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52:790-5